Vaxart (NASDAQ:VXRT – Get Free Report) will issue its quarterly earnings data after the market closes on Monday, May 13th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
Vaxart (NASDAQ:VXRT – Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. The firm had revenue of $3.25 million during the quarter, compared to the consensus estimate of $0.45 million. Vaxart had a negative return on equity of 108.45% and a negative net margin of 1,117.56%. On average, analysts expect Vaxart to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Vaxart Trading Down 1.1 %
NASDAQ:VXRT opened at $0.73 on Wednesday. The stock’s 50 day simple moving average is $1.03 and its 200-day simple moving average is $0.89. Vaxart has a 12-month low of $0.53 and a 12-month high of $1.59. The firm has a market cap of $129.09 million, a P/E ratio of -1.27 and a beta of 0.72.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on Vaxart
About Vaxart
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
Further Reading
- Five stocks we like better than Vaxart
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- How to Read an Earnings Report | Step by Step Guide with Tips
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Datadog: In the Doghouse or Pullback to the Buyzone?
- How to invest in blue chip stocks
- Celsius Stock’s Post-Earnings Morning Dip, Better than Coffee
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.